Profil bibliographique

Mark Lebwohl

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

1411Publications signalées

57358Citations signalées

2Affiliations récentes

Institutions déclarées

Mount Sinai Hospital Icahn School of Medicine at Mount Sinai

Domaines associés

Psoriasis: Treatment and PathogenesisDermatology and Skin DiseasesSpondyloarthritis Studies and TreatmentsAutoimmune Bullous Skin DiseasesPharmaceutical studies and practices

Publications récentes

Accès ouvert 2026 article

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, -TOTAL, and -ADVANCE 1 and 2 Phase 3 Trials

Adis journals on behalf of:, Mark Lebwohl, Melinda Gooderham, Richard B Warren et autres

0 citationsFigshare

Accès ouvert 2026 article

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, -TOTAL, and -ADVANCE 1 and 2 Phase 3 Trials

Adis journals on behalf of:, Mark Lebwohl, Melinda Gooderham, Richard B Warren et autres

0 citationsFigshare

Accès ouvert 2026 article

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Lawrence F. Eichenfield et autres

0 citationsDermatology and Therapy

Accès ouvert 2026 review

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

April W. Armstrong, Bruce Strober, Clive M. Liu, Jennifer C. Cather et autres

0 citationsJournal of Dermatological Treatment

Accès ouvert 2026 article

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Akimichi Morita et autres

0 citationsAmerican Journal of Clinical Dermatology

Accès ouvert 2026 article

Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry

Mark Lebwohl, Ranga Gogineni, Asif Shaikh, Taylor Blachley et autres

0 citationsDermatology and Therapy

2026 article

Nonpruritic Eczematous Flares During Nemolizumab Therapy: A Case Series

Lauren Pabian, Kateryna Karpoff, Mark Lebwohl

0 citationsInternational Journal of Dermatology

Accès ouvert 2026 article

Spesolimab treatment in 2 cases of generalized pustular psoriasis following COVID-19 and corticosteroid withdrawal

Kateryna Karpoff, Sophie Guénin, Kevin Paul, Mark Lebwohl

0 citationsJAAD Case Reports

2026 article

Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study

Marley Cutrona, Sophie Guénin, Mindy Kresch‐Vatch, Rabail Aslam et autres

0 citationsInternational Journal of Dermatology

Accès ouvert 2025 article

Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment

Mark Lebwohl, Darrell S. Rigel, Zeynep Eroglu, Victoria Barghout et autres

0 citationsDermatology and Therapy

2025 article

When profit shapes prescriptions: The dilemma of insurer-driven biologic switching

Dev Patel, Kateryna Karpoff, Mark Lebwohl

0 citationsJournal of the American Academy of Dermatology

Accès ouvert 2025 article

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year

Diamant Thaçi, Akihiko Asahina, Wolf‐Henning Boehncke, Alice B. Gottlieb et autres

0 citationsDermatology and Therapy

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.